These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 19834874

  • 1. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens.
    Yagasaki H, Kobayashi K, Saitou T, Nagamine K, Mitsui Y, Mochizuki M, Kobayashi K, Cho H, Ohyama K, Amemiya S, Nakazawa S.
    Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):195-9. PubMed ID: 19834874
    [Abstract] [Full Text] [Related]

  • 2. Treatment with insulin glargine does not suppress serum IGF-1.
    Slawik M, Schories M, Busse Grawitz A, Reincke M, Petersen KG.
    Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
    [Abstract] [Full Text] [Related]

  • 3. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes.
    Ekström K, Salemyr J, Zachrisson I, Carlsson-Skwirut C, Ortqvist E, Bang P.
    Diabetes Care; 2007 Jun; 30(6):1357-63. PubMed ID: 17372150
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factors and their binding proteins in children with IDDM.
    Wacharasindhu S, Srivuthana S, Aroonparkmongkol S.
    J Med Assoc Thai; 2002 Jan; 85(1):41-52. PubMed ID: 12075719
    [Abstract] [Full Text] [Related]

  • 5. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
    Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G.
    Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
    [Abstract] [Full Text] [Related]

  • 6. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients?
    Lindgren BF, Odar-Cederlöf I, Ericsson F, Brismar K.
    Growth Regul; 1996 Sep; 6(3):137-43. PubMed ID: 8894646
    [Abstract] [Full Text] [Related]

  • 7. Increased 24 h mean insulin-like growth factor binding protein-3 proteolytic activity in pubertal type 1 diabetic boys.
    Zachrisson I, Brismar K, Carlsson-Skwirut C, Dahlquist G, Wallensteen M, Bang P.
    Growth Horm IGF Res; 2000 Dec; 10(6):324-31. PubMed ID: 11161963
    [Abstract] [Full Text] [Related]

  • 8. Inverse changes in fetal insulin-like growth factor (IGF)-1 and IGF binding protein-1 in association with higher birth weight in maternal diabetes.
    Lindsay RS, Westgate JA, Beattie J, Pattison NS, Gamble G, Mildenhall LF, Breier BH, Johnstone FD.
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):322-8. PubMed ID: 17302863
    [Abstract] [Full Text] [Related]

  • 9. No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance.
    Ricart W, Fernández-Real JM.
    Obes Res; 2001 Oct; 9(10):631-6. PubMed ID: 11595780
    [Abstract] [Full Text] [Related]

  • 10. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
    Rosak C, Jung R, Hofmann U.
    Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
    [Abstract] [Full Text] [Related]

  • 11. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.
    Cotterill AM, Daly F, Holly JM, Hughes SC, Camacho-Hübner C, Abdulla AF, Gale EA, Savage MO.
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941
    [Abstract] [Full Text] [Related]

  • 12. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD.
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [Abstract] [Full Text] [Related]

  • 13. [Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy].
    Peczyńska J, Urban M, Głowińska B, Urban B.
    Pol Merkur Lekarski; 2003 Apr; 14(82):336-9. PubMed ID: 12868196
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M.
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [Abstract] [Full Text] [Related]

  • 15. Semilente-insulin at bedtime is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type-I-diabetes.
    Holl RW, Teller WM, Heinze E.
    Exp Clin Endocrinol Diabetes; 1996 Jul; 104(5):360-4. PubMed ID: 8957270
    [Abstract] [Full Text] [Related]

  • 16. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM, Yuen K, White D, Mallard B, Dalton RN, Acerini CL, Dunger DB.
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [Abstract] [Full Text] [Related]

  • 17. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM.
    Kobayashi K, Amemiya S, Sawanobori E, Higashida K, Ishihara T, Kobayashi K, Kato K, Nakazawa S.
    Diabetes Care; 1997 Sep; 20(9):1442-7. PubMed ID: 9283794
    [Abstract] [Full Text] [Related]

  • 18. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
    Hedman CA, Frystyk J, Lindström T, Oskarsson P, Arnqvist HJ.
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.